Tower Research Capital LLC TRC raised its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 205.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 916 shares of the company’s stock after buying an additional 616 shares during the period. Tower Research Capital LLC TRC’s holdings in Zimmer Biomet Holdings were worth $110,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. Ameriprise Financial Inc. boosted its stake in shares of Zimmer Biomet Holdings by 38.9% in the second quarter. Ameriprise Financial Inc. now owns 4,853,226 shares of the company’s stock valued at $584,179,000 after buying an additional 1,359,249 shares during the last quarter. Vanguard Group Inc. boosted its stake in Zimmer Biomet Holdings by 12.3% in the second quarter. Vanguard Group Inc. now owns 11,940,582 shares of the company’s stock worth $1,437,408,000 after buying an additional 1,306,447 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in Zimmer Biomet Holdings during the second quarter worth approximately $131,659,000. Bank of New York Mellon Corp boosted its stake in Zimmer Biomet Holdings by 28.8% in the second quarter. Bank of New York Mellon Corp now owns 2,227,774 shares of the company’s stock worth $268,181,000 after buying an additional 497,842 shares in the last quarter. Finally, Atalanta Sosnoff Capital LLC purchased a new stake in Zimmer Biomet Holdings during the second quarter worth approximately $42,984,000. Institutional investors own 88.30% of the company’s stock.
Zimmer Biomet Holdings Inc. (NYSE:ZBH) opened at 126.91 on Friday. The firm’s 50-day moving average is $128.10 and its 200 day moving average is $121.94. The stock has a market capitalization of $25.38 billion, a price-to-earnings ratio of 115.90 and a beta of 0.95. Zimmer Biomet Holdings Inc. has a 1-year low of $88.27 and a 1-year high of $133.21.
Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, July 28th. The company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.97 by $0.05. The company had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.90 billion. Zimmer Biomet Holdings had a return on equity of 16.12% and a net margin of 1.68%. The firm’s revenue was up 65.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.58 earnings per share. Equities analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.97 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 23rd will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date is Wednesday, September 21st. Zimmer Biomet Holdings’s payout ratio is currently 157.38%.
ZBH has been the subject of a number of recent analyst reports. Piper Jaffray Cos. restated an “overweight” rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, June 21st. Jefferies Group restated a “buy” rating and issued a $150.00 price objective on shares of Zimmer Biomet Holdings in a research report on Monday, August 8th. Argus restated a “buy” rating and issued a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Thursday, September 22nd. Barclays PLC upped their price objective on shares of Zimmer Biomet Holdings from $140.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, August 23rd. Finally, RBC Capital Markets set a $143.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Wednesday, September 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty-one have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $133.57.
In other news, insider Stuart G. Kleopfer sold 533 shares of the business’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $132.71, for a total value of $70,734.43. Following the transaction, the insider now owns 6,397 shares of the company’s stock, valued at $848,945.87. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Tony W. Collins sold 1,287 shares of the business’s stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $129.16, for a total value of $166,228.92. The disclosure for this sale can be found here. 1.22% of the stock is owned by insiders.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.